Microdosing of Psychoactive Substances in Business Practice
2. Psychoactive Substances
- By their common effects (effects they all have) in the brain and body—for example, stimulants and depressants;
- By their likelihood to cause addiction (high to low);
- By their chemical structure; and
- By U.S. Drug Enforcement Administration Schedules I–V, which classify these drugs by the potential for abuse .
3. The Use and Effects of Microdosing in Business
A male twenty-five with a master’s degree from Stanford works for a tech startup in San Francisco, making a little bit of everything: hardware and software design, sales and business development. He has recently discovered a new way to enhance his productivity and creativity, and it is not Five Hour Energy or meditation. He is one of a growing number of professionals who enjoy taking “microdoses” of psychedelics—in his free time and, occasionally, at the office. “I had an epic time,” he says at the end of one such day. “I was making many sales, talking to many people, finding solutions to their technical problems.”.
3.2. The Effects of Psychedelics Microdosing
In the Polito and Stevenson study , 98 participants (recruited from Reddit and Bluelight microdosing discussion communities) were asked to provide daily overviews of their microdosing experiences via email and complete a questionnaire at the start and end of the experiment. The experiment took place over six weeks and found that participants felt an increase across all psychological functions (well-being, mindfulness, creativity, attention, etc.) measured on the days they took the microdose. This increase did not continue over the following days, but focus and productivity rose two days after taking the dose (most users tend to have one day on and a few days off. Participants mentioned a reduction in mind wandering, lower levels of depression and stress, and a rise in absorption (being absorbed in mental imagery) which are all fantastic tools for working. Though, creativity and general quality of life were not reported to change at all.
Steve Jobs was said to have partaken in psychedelics and playfully derided his rival, Bill Gates, as being “unimaginative” and suggested dropping some LSD. Scott Adams, the creator of the Dilbert cartoon strip, pundit on YouTube and Periscope and resident of Northern California, claims that he took mushrooms once and it was the best day of his life, and he no longer felt any limits to his life and career success. Joe Rogan, the host of one of the most listened-to podcasts and another California resident, is a big proponent of psychedelic microdosing and has had numerous guests on his shows, ranging from scientists to MMA fighters, who have shared their positive experiences from microdosing.
A female 40, describes her reasons to microdose as “I will take some this Wednesday because my business is expanding and I am designing that day. Microdosing will help with the creative side. I will take some on Thursday because I am trying to upskill one of the managers, and it helps with my human interaction and empathy. However, if I knew I was going to be sitting at home doing the bookkeeping and looking at spreadsheets for hours, I would not microdose—I would get distracted”.
3.3. The Microdosing Business
Male 29, working in the Silicon Valley, describes his everyday experience under the guidance of a professional psychedelic coach: “In that altered state, it became much more real than I did not know anything about the world,” says he. “We realized how ignorant we were and how much growth we had left in our lives. It was, in a strange way, very humbling but also very liberating. That helped me understand my potential.”.
4. Microdosing at the Workplace
A female 34, has been facing court after being accused of illegal handling of psychoactive substances. The matter of legal action is financing medicinal drugs being used to produce methamphetamine and transport for the cook to purchase medicines, sell methamphetamine, and the illicit laboratory for production. When caught by the criminal police, she had several grams of methamphetamine with her. “I am an occasional user. I take it as a booster helping me to go through a huge load of work”.
Czech critical infrastructure company has raised a flag against psychoactive substances microdosing. Full-size contamination mapping went through the company’s premises, especially the national control room. Every control was thoroughly searched and analyzed with Mistral wet chemistry tests and a nearby changing room. There was a strong trace of marijuana smoked in the changing room ventilated through the window with joined subtle traces of cannabinoids on the office desks, probably delivered by the sleeves of smokers. The trace pathway was interrupted in the middle section by regular cleaning, so the trace pathway seems to be of an older pattern. Significant evidence of continuous contamination was found between the palm scanner at the door entrance and office desks. According to instructions, there was no origin of the contamination—either pain killers or targeted abuse of the psychoactive substance.Later, samples from common spaces at the office wings—kitchenettes, showers, printers—were also analyzed. At the southern office wing, there was found a strong, located trace of cannabinoids, later recognized according to the noticeable part of grease as a probable medicinal cannabinoid salve. A good hit was made in the showers of top management, where significant traces of amphetamine were found. Without further analysis, there was no chance to identify whether there were traces of abuse of psychoactive substances or medical treatment. At the northern office wing, there were many traces of pseudoephedrine in every kitchenette, likely due to cold medicines. A substantial hit was made on rough particles of marijuana dry matter, which was evidence of abuse of cannabis in the workplace.
Conflicts of Interest
- WHO. Management of Substance Abuse. Available online: https://www.who.int/substance_abuse/terminology/psychoactive_substances/en/ (accessed on 27 February 2021).
- Hartney, E. The Different Types of Psychoactive Drugs. Verywellmind. Available online: https://www.verywellmind.com/what-is-psychoactive-22500 (accessed on 23 November 2021).
- Lehmert, K.; Hamplova, N. Copping a Microdose; CBRNe World: Winchester, UK, 2018; Volume 5, pp. 30–34. ISSN 2040-2074. [Google Scholar]
- Karila, L.; Zarmdini, R.; Petit, A.; Lafaye, G.; Lowenstein, W.; Reynaud, M. Cocaine addiction: Current data for the clinician. Presse Méd. 2014, 43, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Sordo, L.; Indave, B.I.; Barrio, G.; Degenhardt, L.; De La Fuente, L.; Bravo, M.J. Cocaine use and risk of stroke: A systematic review. Drug Alcohol Depend. 2014, 142, 1–13. Available online: https://www.sciencedirect.com/science/article/abs/pii/S0376871614009685?via%3Dihub (accessed on 30 March 2021). [CrossRef] [PubMed]
- Pomara, C.; Cassano, T.; D’errico, S.; Bello, S.; Romano, A.D.; Riezzo, I.; Serviddio, G. Data available on the extent of cocaine use and dependence: Biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. Curr. Med.-Chem. 2012, 19, 5647–5657. Available online: https://pubmed.ncbi.nlm.nih.gov/22856655/ (accessed on 30 March 2021). [CrossRef] [PubMed]
- Sharma, H.S.; Muresanu, D.; Sharma, A.; Patnaik, R. Cocaine-induced breakdown of the blood-brain barrier and neurotoxicity. Int. Rev. Neurobiol. 2009, 88, 297–334. Available online: https://pubmed.ncbi.nlm.nih.gov/19897082/ (accessed on 15 March 2021). [CrossRef] [PubMed]
- Karch, S.B. Karch’s Pathology of Drug Abuse, 4th ed.; CRC Press: Boca Raton, FL, USA, 2009; p. 70. ISBN 978-0-8493-7881-2. [Google Scholar]
- Aizpurua-Olaizola, O.; Soydaner, U.; Öztürk, E.; Schibano, D.; Simsir, Y.; Navarro, P.; Etxebarria, N.; Usobiaga, A. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J. Nat. Prod. 2016, 79, 324–331. [Google Scholar] [CrossRef]
- Lambert, D.M.; Fowler, C.J. The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. 2005, 48, 5059–5087. [Google Scholar] [CrossRef] [PubMed]
- Ameri, A. The effects of cannabinoids on the brain. Prog. Neurobiol. 1999, 58, 315–348. [Google Scholar] [CrossRef]
- Siegel, G.J. Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 7th ed.; Elsevier: Amsterdam, The Netherlands, 2006; ISBN 978-0-08-047207-2. [Google Scholar]
- Smigielski, L.; Scheidegger, M.; Kometer, M.; Vollenweider, F.X. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. NeuroImage 2019, 196, 207–215. Available online: https://www.sciencedirect.com/science/article/abs/pii/S1053811919302952?via%3Dihub (accessed on 15 March 2021). [CrossRef] [PubMed]
- Palhano-Fontes, F.; Andrade, K.C.; Tofoli, L.F.; Santos, A.C.; Crippa, J.A.S.; Hallak, J.E.C.; Ribeiro, S.; de Araujo, D.B. The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network. PLoS ONE 2015, 10, e0118143. Available online: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118143 (accessed on 18 February 2021). [CrossRef][Green Version]
- Letheby, C.; Gerrans, P. Self unbound: Ego dissolution in psychedelic experience. Neurosci. Conscious. 2017, 3, nix016. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007152/ (accessed on 12 February 2021). [CrossRef] [PubMed][Green Version]
- Milliere, R.; Carhart-Harris, R.L.; Roseman, L.; Trautwein, F.-M.; Berkovich-Ohana, A. Psychedelics, meditation, and self-consciousness. Front. Psychol. 2018, 9, 1475. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137697/ (accessed on 3 March 2021). [CrossRef] [PubMed]
- Griffiths, R.R.; Richards, W.A.; McCann, U.; Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006, 187, 268–283, discussion 284–292. [Google Scholar] [CrossRef] [PubMed]
- Timmermann, C.; Roseman, L.; Williams, L.; Erritzoe, D.; Martial, C.; Cassol, H.; Laureyes, S.; Tt, D.; Carhart-Harris, R. DMT models the near-death experience. Front. Psychol. 2018, 9, 1424. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107838/ (accessed on 15 March 2021). [CrossRef] [PubMed][Green Version]
- Fadiman, J. Microdose Research: Without Approvals, Control Groups, Double Blinds, Staff or Funding; Psychedelic Press: London, UK; Available online: https://www.researchgate.net/publication/308138461_Microdose_research_without_approvals_control_groups_double_blinds_staff_or_funding (accessed on 31 January 2021).
- Brodwin, E. The Truth about ‘Microdosing’, which Involves Taking Tiny Amounts of Psychedelics like LSD. Business Insider. Available online: https://www.businessinsider.com/microdosing-lsd-effects-risks-2017-1 (accessed on 30 January 2021).
- Dahl, H. A Brief History of LSD in the Twenty-First Century; Psychedelic Press: London, UK; Available online: http://psypressuk.com/2015/07/07/a-brief-history-of-lsd-in-the-twenty-first-century/ (accessed on 18 February 2021).
- Webb, M.; Copes, H.; Hendricks, P.S. Narrative identity, rationality, and microdosing classic psychedelics. Int. J. Drug Policy 2019, 70, 33–39. Available online: https://www.sciencedirect.com/science/article/abs/pii/S0955395919301161?via%3Dihub (accessed on 3 March 2021). [CrossRef] [PubMed]
- Polito, V.; Stevenson, R.J. A systematic study of microdosing psychedelics. PLoS ONE 2019, 14, e0211023. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364961/ (accessed on 2 April 2021). [CrossRef] [PubMed][Green Version]
- Preller, K.H. The effects of low doses of lysergic acid diethylamide in healthy humans: Demystifying the microdosing of psychedelics. Biol. Psychiatr. 2019, 86, 736–737. Available online: https://www.biologicalpsychiatryjournal.com/article/S0006-3223(19)31660-9/abstract (accessed on 2 April 2021). [CrossRef] [PubMed]
- Leonard, A. How LSD Microdosing Became the Hot New Business Trip. Rolling Stone. 2015. Available online: https://www.rollingstone.com/culture/culture-news/how-lsd-microdosing-became-the-hot-new-business-trip-64961/ (accessed on 20 March 2021).
- Anderson, B. Can a Low Dose Go a Long Way? Motherboard, 2013. Available online: https://motherboard.vice.com/en_us/article/wnnmd5/can-a-low-dose-go-a-long-way-5886b6e705557845e1757bba (accessed on 12 February 2021).
- Williams, A. How LSD Saved One Woman’s Marriage. The New York Times. 7 January 2017. Available online: https://www.nytimes.com/2017/01/07/style/microdosing-lsd-ayelet-waldman-michael-chabon-marriage.html?_r=0 (accessed on 7 January 2017).
- Kelly, J. Silicon Valley Is Micro-Dosing ‘Magic Mushrooms’ to Boost Their Careers. Forbes. Available online: https://www.forbes.com/sites/jackkelly/2020/01/17/silicon-valley-is-micro-dosing-magic-mushrooms-to-boost-their-careers/?sh=5e0435e15822 (accessed on 17 January 2021).
- Sahakian, B.; D’Angelo, C.; Savulich, G. Microdosing’ LSD Is Not Just a Silicon Valley Trend–It Is Spreading to Other Workplaces. Independent. Available online: https://www.independent.co.uk/voices/lsd-microdosing-california-silicon-valley-california-drugs-young-professionals-a8259001.html (accessed on 17 March 2021).
- Hagerty, C. Following the Popularity of ‘Microdosing’ Psychedelics to Improve Productivity, Some Are Turning to these Substances for Career Clarity; Worklife. Available online: https://www.bbc.com/worklife/article/20200106-can-drugs-help-you-choose-a-new-career (accessed on 6 January 2021).
- Souli, S. Psychedelics and the workplace. J. Beautiful Bus. Available online: https://journalofbeautifulbusiness.com/psychedelics-and-the-workplace-e2337f60c9a2 (accessed on 7 March 2021).
- De Vries, N. This Dutch Startup Sells Microdosing Kits to Boost Productivity—So I Did Magic Truffles for a Month. TNW. Available online: https://thenextweb.com/growth-quarters/2020/10/23/legal-microdosing-shrooms-psilocybin-productvity-boost/ (accessed on 23 October 2020).
- Piece of Mind Cannabis: Can You Benefit from Microdosing Marihuana? WhatcomTalk, Inc. 2021. Available online: https://www.whatcomtalk.com/2021/02/25/can-you-benefit-from-microdosing-marijuana/ (accessed on 4 April 2021).
- Cameron, C.; Watson, D.; Robinson, J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder–related insomnia and nightmares, chronic pain, harm reduction, and other indications. J. Clin. Psychopharmacol. 2014, 34, 559–564. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Biskup, P. Nákup Léků k Výrobě Drog Měla Financovat Pracovnice Ministerské Organizace. Novinky. Available online: https://www.novinky.cz/krimi/clanek/nakup-leku-k-vyrobe-drog-mela-financovat-pracovnice-ministerske-organizace-40349612 (accessed on 1 February 2021).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Lehmert, K.; Ambrozova, E.; Pokorny, V.; Kolenak, J. Microdosing of Psychoactive Substances in Business Practice. Businesses 2021, 1, 196-204. https://doi.org/10.3390/businesses1030014
Lehmert K, Ambrozova E, Pokorny V, Kolenak J. Microdosing of Psychoactive Substances in Business Practice. Businesses. 2021; 1(3):196-204. https://doi.org/10.3390/businesses1030014Chicago/Turabian Style
Lehmert, Karel, Eva Ambrozova, Vratislav Pokorny, and Jiri Kolenak. 2021. "Microdosing of Psychoactive Substances in Business Practice" Businesses 1, no. 3: 196-204. https://doi.org/10.3390/businesses1030014